Humanigen Inc (HGEN)

• $0.15

  $0.15

  $0.15
  

  2.93%

  Downside

  Day's Volatility :4.34%

  Upside

  1.45%

  
• $0.09

  $3.25

  $0.15
  

  38.4%

  Downside

  52 Weeks Volatility :97.16%

  Upside

  95.38%

  

Returns

What analysts predicted

Upside of 121.48%

• BlackRock Inc

  0.79%

• Bank of New York Mellon Corp

  0.74%

• Vanguard Group Inc

  0.59%

• Geode Capital Management, LLC

  0.41%

• Telemetry Investments, L.L.C.

  0.39%

• UBS Group AG

  0.17%

• Humanigen Inc Earnings

  Humanigen Inc’s price-to-earnings ratio stands at None

  Read More

Humanigen, Inc. is developing its portfolio of Humaneered® monoclonal antibodies to address cutting-edge CAR-T optimization and oncology treatments advancing safer, better, and more effective cancer therapies. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential biologic therapy to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as CMML and JMML. Ifabotuzumab, which targets the Eph type-A receptor 3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, both as naked antibody and as part of an antibody-drug conjugate, as well as a backbone for a novel CAR-T construct, and a bispecific antibody platform.